Cambridge Investment Research Advisors
PGEN icon

Cambridge Investment Research Advisors’s Precigen PGEN Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$269K Buy
47,194
+19,200
+69% +$83K ﹤0.01% 3545
2026
Q1 		$108K Hold
27,994
– – ﹤0.01% 3784
2025
Q4 		$117K Sell
27,994
-13,235
-32% -$51.2K ﹤0.01% 3685
2025
Q3 		$136K Sell
41,229
-125,000
-75% -$353K ﹤0.01% 3560
2025
Q2 		$236K Sell
166,229
-25,490
-13% -$36.2K ﹤0.01% 3191
2025
Q1 		$286K Sell
191,719
-29,000
-13% -$45.7K ﹤0.01% 2907
2024
Q4 		$247K Buy
220,719
+72,884
+49% +$62.2K ﹤0.01% 3003
2024
Q3 		$140K Buy
147,835
+71,035
+92% +$89.6K ﹤0.01% 3220
2024
Q2 		$121K Sell
76,800
-1,384
-2% -$2.01K ﹤0.01% 3133
2024
Q1 		$113K Buy
78,184
+8,800
+13% +$12.6K ﹤0.01% 3140
2023
Q4 		$93K Sell
69,384
-12,150
-15% -$14.3K ﹤0.01% 3046
2023
Q3 		$116K Buy
81,534
+6,000
+8% +$8.5K ﹤0.01% 2944
2023
Q2 		$87K Buy
75,534
+8,625
+13% +$10.2K ﹤0.01% 3025
2023
Q1 		$71K Buy
66,909
+18,250
+38% +$26.3K ﹤0.01% 2999
2022
Q4 		$74K Sell
48,659
-2,545
-5% -$4.38K ﹤0.01% 2942
2022
Q3 		$109K Sell
51,204
-7,685
-13% -$16.2K ﹤0.01% 2836
2022
Q2 		$79K Sell
58,889
-5,101
-8% -$7.57K ﹤0.01% 2894
2022
Q1 		$135K Buy
63,990
+3,475
+6% +$8.46K ﹤0.01% 2964
2021
Q4 		$225K Sell
60,515
-10,037
-14% -$43.2K ﹤0.01% 2774
2021
Q3 		$352K Buy
70,552
+2,850
+4% +$16.4K ﹤0.01% 2329
2021
Q2 		$441K Buy
67,702
+11,899
+21% +$83.1K ﹤0.01% 2151
2021
Q1 		$384K Buy
55,803
+5,151
+10% +$43.5K ﹤0.01% 2097
2020
Q4 		$517K Sell
50,652
-23,930
-32% -$155K ﹤0.01% 1749
2020
Q3 		$261K Buy
74,582
+4,225
+6% +$20.1K ﹤0.01% 2044
2020
Q2 		$351K Sell
70,357
-1,225
-2% -$4.17K ﹤0.01% 1764
2020
Q1 		$243K Buy
71,582
+11,085
+18% +$47.8K ﹤0.01% 1813
2019
Q4 		$332K Buy
60,497
+4,350
+8% +$24.5K ﹤0.01% 1847
2019
Q3 		$321K Sell
56,147
-2,809
-5% -$19.1K ﹤0.01% 1772
2019
Q2 		$452K Buy
58,956
+2,600
+5% +$14K ﹤0.01% 1495
2019
Q1 		$296K Buy
56,356
+10,533
+23% +$73K ﹤0.01% 1815
2018
Q4 		$300K Buy
45,823
+1,835
+4% +$20.6K ﹤0.01% 1669
2018
Q3 		$757K Sell
43,988
-10,652
-19% -$158K 0.01% 1201
2018
Q2 		$762K Sell
54,640
-16,515
-23% -$279K 0.01% 1147
2018
Q1 		$1.09M Buy
71,155
+7,420
+12% +$106K 0.01% 895
2017
Q4 		$734K Sell
63,735
-811
-1% -$12.1K 0.01% 1073
2017
Q3 		$1.23M Sell
64,546
-3,444
-5% -$70.9K 0.02% 742
2017
Q2 		$1.64M Sell
67,990
-14,680
-18% -$322K 0.02% 595
2017
Q1 		$1.64M Buy
82,670
+1,925
+2% +$43K 0.03% 513
2016
Q4 		$1.95M Buy
80,745
+8,753
+12% +$244K 0.04% 447
2016
Q3 		$2M Sell
71,992
-2,166
-3% -$57.3K 0.04% 433
2016
Q2 		$1.81M Sell
74,158
-4,778
-6% -$136K 0.04% 407
2016
Q1 		$2.65M Sell
78,936
-2,866
-4% -$90.2K 0.06% 295
2015
Q4 		$2.44M Buy
81,802
+59,195
+262% +$2M 0.06% 299
2015
Q3 		$712K Buy
+22,607
New +$1.1M 0.02% 607
2014
Q4 		– Sell
-17,160
Closed -$305K – 1455
2014
Q3 		$305K Buy
+17,160
New +$350K 0.01% 1088

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $3.05B AUM 42.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cambridge Investment Research Advisors's PGEN Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Precigen (PGEN) stake by 69% in Q2 2026, buying an estimated $83K and bringing the position to 47,194 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #3545.

Cambridge Investment Research Advisors first reported a position in PGEN in Q3 2014 and has held it in 45 quarters since. The position peaked at $2.65M in Q1 2016. 211 funds tracked by Wall St. Rank hold PGEN as of Q2 2026.

  • Cambridge Investment Research Advisors held 47,194 shares of Precigen worth $269K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 19,200 Precigen shares in Q2 2026, an estimated $83K.
  • Precigen made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3545 holding.
  • Cambridge Investment Research Advisors first reported a position in Precigen in Q3 2014 and has held it in 45 quarters since.
  • Cambridge Investment Research Advisors's Precigen position peaked at $2.65M in Q1 2016.
  • 211 funds tracked by Wall St. Rank held Precigen as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.